Subtopic Deep Dive

PRMT5 in Cancer Epigenetics
Research Guide

What is PRMT5 in Cancer Epigenetics?

PRMT5 is a protein arginine methyltransferase that catalyzes symmetric dimethylarginine modifications on histones and non-histone proteins to regulate gene expression in cancer epigenetics.

PRMT5 overexpression drives epigenetic silencing of tumor suppressors in cancers like MCL. Chan-Penebre et al. (2015) developed a selective PRMT5 inhibitor with in vivo potency in MCL models (531 citations). Stopa et al. (2015) detailed PRMT5's roles in cancer development (492 citations). Branscombe et al. (2001) identified PRMT5 as the enzyme forming symmetric dimethylarginine (360 citations).

Curated Papers

Key Challenges

Why It Matters

PRMT5 inhibitors restore tumor suppressor expression, showing efficacy in MCL and other cancers (Chan-Penebre et al., 2015). Dysregulated PRMT5 methylation alters chromatin accessibility, collaborating with genetic mutations in oncogenesis (Lund and van Lohuizen, 2004). Structural insights from the PRMT5:MEP50 complex enable rational inhibitor design (Antonysamy et al., 2012). Clinical trials target PRMT5 for precision therapies in epigenetically driven tumors.

Key Research Challenges

PRMT5 Inhibitor Selectivity

Developing inhibitors that distinguish PRMT5 from other methyltransferases remains difficult due to conserved active sites. Chan-Penebre et al. (2015) reported a selective inhibitor effective in MCL models. Structural data from Antonysamy et al. (2012) highlights MEP50 cofactor interactions complicating specificity.

PRMT5 Substrate Identification

Identifying non-histone substrates modified by PRMT5 in cancer cells is incomplete. Stopa et al. (2015) cataloged diverse PRMT5 roles beyond histones. Branscombe et al. (2001) characterized symmetric dimethylarginine formation but full substrate mapping lags.

PRMT5 in Tumor Microenvironment

Understanding PRMT5's role in immune evasion and stromal interactions in cancers is underexplored. Zhang and Reinberg (2001) linked histone methylation to gene regulation, yet cancer-specific contexts need clarification. Protein stability controls via methylation add complexity (Lee et al., 2023).

Essential Papers

Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails

Yi Zhang, Danny Reinberg · 2001 · Genes & Development · 1.5K citations

Department of Biochemistry and Biophysics, Curriculum in Genetics and Molecular Biology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, North Carolina 27599-72...

Control of protein stability by post-translational modifications

Ji Min Lee, Henrik M. Hammarén, Mikhail M. Savitski et al. · 2023 · Nature Communications · 646 citations

Transcriptional Regulation by P53

Rachel Beckerman, Carol Prives · 2010 · Cold Spring Harbor Perspectives in Biology · 573 citations

Inactivation of p53 is critical for the formation of most tumors. Illumination of the key function(s) of p53 protein in protecting cells from becoming cancerous is therefore a worthy goal. Arguably...

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · 2015 · Nature Chemical Biology · 531 citations

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

Nicole Stopa, Jocelyn E. Krebs, David Shechter · 2015 · Cellular and Molecular Life Sciences · 492 citations

Epigenetic mechanisms in mammals

J. K. Kim, Mala Samaranayake, Sriharsa Pradhan · 2008 · Cellular and Molecular Life Sciences · 489 citations

DNA and histone methylation are linked and subjected to mitotic inheritance in mammals. Yet how methylation is propagated and maintained between successive cell divisions is not fully understood. A...

Epigenetics and cancer

Anders H. Lund, Maarten van Lohuizen · 2004 · Genes & Development · 481 citations

Epigenetic mechanisms act to change the accessibility of chromatin to transcriptional regulation locally and globally via modifications of the DNA and by modification or rearrangement of nucleosome...

Reading Guide

Foundational Papers

Start with Branscombe et al. (2001) for PRMT5 discovery and symmetric dimethylarginine mechanism, then Zhang and Reinberg (2001, 1505 citations) for histone methylation regulation, followed by Lund and van Lohuizen (2004) linking epigenetics to cancer.

Recent Advances

Study Chan-Penebre et al. (2015) for PRMT5 inhibitors in MCL and Antonysamy et al. (2012) for structural basis; Lee et al. (2023) covers methylation in protein stability.

Core Methods

Core techniques include crystal structures (Antonysamy et al., 2012), inhibitor assays (Chan-Penebre et al., 2015), ChIP-seq for H3R8me2 mapping, and mass spectrometry for arginine methylation (Branscombe et al., 2001).

How PapersFlow Helps You Research PRMT5 in Cancer Epigenetics

Discover & Search

Research Agent uses searchPapers and exaSearch to find PRMT5 inhibitor studies, then citationGraph on Chan-Penebre et al. (2015) reveals 500+ citing papers on clinical analogs. findSimilarPapers expands to MEP50 complex structures like Antonysamy et al. (2012).

Analyze & Verify

Analysis Agent applies readPaperContent to parse Chan-Penebre et al. (2015) inhibitor IC50 data, then runPythonAnalysis with pandas to plot dose-response curves from extracted tables. verifyResponse via CoVe cross-checks claims against Stopa et al. (2015), with GRADE scoring evidence strength for symmetric dimethylarginine roles.

Synthesize & Write

Synthesis Agent detects gaps in PRMT5-p53 interactions by flagging contradictions between Beckerman and Prives (2010) and methylation data. Writing Agent uses latexEditText for inhibitor mechanism sections, latexSyncCitations for 20+ references, and latexCompile for full review manuscripts. exportMermaid generates PRMT5-histone modification pathway diagrams.

Use Cases

"Analyze PRMT5 inhibitor dose-response from Chan-Penebre 2015 and compute EC50 via Python"

Research Agent → searchPapers('PRMT5 inhibitor MCL') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas curve fitting) → matplotlib EC50 plot and stats output.

"Write LaTeX review section on PRMT5 epigenetics in cancer with citations"

Synthesis Agent → gap detection on 10 papers → Writing Agent → latexEditText(draft text) → latexSyncCitations(Chan-Penebre 2015 et al.) → latexCompile → PDF with figures.

"Find GitHub repos with PRMT5 structural models from Antonysamy 2012"

Research Agent → paperExtractUrls(Antonysamy 2012) → paperFindGithubRepo → githubRepoInspect → code for PRMT5:MEP50 docking simulations.

Automated Workflows

Deep Research workflow scans 50+ PRMT5 papers via citationGraph from Branscombe et al. (2001), producing structured reports on inhibitor progress. DeepScan applies 7-step CoVe to verify claims in Stopa et al. (2015) against clinical data. Theorizer generates hypotheses on PRMT5-pRB repression links from Frolov and Dyson (2004).

Try Doxa for PRMT5 in Cancer Epigenetics Research

Frequently Asked Questions

What defines PRMT5 activity in epigenetics?

PRMT5 catalyzes symmetric dimethylarginine on histones H3/H4 and non-histones, repressing transcription (Branscombe et al., 2001; Zhang and Reinberg, 2001).

What are key methods for PRMT5 inhibition?

Selective small-molecule inhibitors target the PRMT5:MEP50 SAM-binding site, validated in MCL xenografts (Chan-Penebre et al., 2015; Antonysamy et al., 2012).

What are seminal papers on PRMT5 in cancer?

Chan-Penebre et al. (2015, 531 citations) on inhibitors; Stopa et al. (2015, 492 citations) on cancer roles; Branscombe et al. (2001, 360 citations) on enzyme discovery.

What open problems exist in PRMT5 research?

Unresolved substrates in tumor suppressors like p53, inhibitor resistance mechanisms, and combinatorial therapies with HDAC inhibitors need exploration.